

Hans C Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1698704/publications.pdf>

Version: 2024-02-01

38
papers

1,374
citations

687363

13
h-index

361022

35
g-index

38
all docs

38
docs citations

38
times ranked

1670
citing authors

#	ARTICLE	IF	CITATIONS
1	Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2020, 21, 207-221.	10.7	544
2	Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. <i>New England Journal of Medicine</i> , 2021, 385, 46-58.	27.0	268
3	Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. <i>Blood</i> , 2020, 136, 71-80.	1.4	146
4	Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. <i>Lancet Haematology</i> , the, 2019, 6, e266-e275.	4.6	68
5	Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1948-1954.	2.0	63
6	Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma. <i>Leukemia</i> , 2021, 35, 255-258.	7.2	48
7	A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis. <i>Blood Advances</i> , 2019, 3, 2400-2408.	5.2	28
8	The Imipridone ONC201 Induces Apoptosis and Overcomes Chemotherapy Resistance by Up-Regulation of Bim in Multiple Myeloma. <i>Neoplasia</i> , 2017, 19, 772-780.	5.3	22
9	The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072097981.	2.5	18
10	Descriptive Analysis of Isatuximab Use Following Prior Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 20-21.	1.4	18
11	A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma. <i>Blood Cancer Journal</i> , 2019, 9, 80.	6.2	17
12	Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 560-569.	0.4	17
13	Novel Approaches to Treatment of Double-Refractory Multiple Myeloma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, e302-e306.	3.8	17
14	Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM. <i>Blood Advances</i> , 2020, 4, 4834-4837.	5.2	11
15	Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis. <i>Clinical Cancer Research</i> , 2019, 25, 6781-6787.	7.0	10
16	Cardiac Magnetic Resonance Predicting Outcomes Among Patients at Risk for Cardiac AL Amyloidosis. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 626414.	2.4	8
17	Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance. <i>Leukemia and Lymphoma</i> , 2022, 63, 710-721.	1.3	8
18	KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma. <i>Bone Marrow Transplantation</i> , 2022, 57, 1142-1149.	2.4	7

#	ARTICLE	IF	CITATIONS
19	Progressive Multifocal Leukoencephalopathy After Allogeneic Bone Marrow Transplantation for Acute Myeloid Leukemia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1660-1664.	4.9	5
20	Practical Approaches to the Management of Dual Refractory Multiple Myeloma. <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 148-155.	2.3	5
21	MM-250: Impact of Prolonged Dose Delays on Response with Belantamab Mafodotin (Belamaf); Tj ETQq1 1 0.784314 rgBT /Overlock Leukemia, 2020, 20, S304-S305.	0.4	5
22	Treatment patterns and outcomes in elderly patients with newly diagnosed multiple myeloma: results from the Connect [®] MM Registry. <i>Blood Cancer Journal</i> , 2021, 11, 134.	6.2	5
23	Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1077-1083.	2.0	4
24	Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma. <i>Clinical Cancer Research</i> , 2022, 28, 1277-1284.	7.0	4
25	Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	4
26	Gene expression profiling predicts relapse-free and overall survival in newly diagnosed myeloma patients treated with novel therapies. <i>British Journal of Haematology</i> , 2021, 192, e115-e120.	2.5	3
27	Serum paraprotein persistence and size determine outcome in a cohort of patients with a modern definition of plasmacytoma with up to 19 years of follow up. <i>Blood Cancer Journal</i> , 2021, 11, 17.	6.2	3
28	Outcomes of lenalidomide retreatment with novel triplet regimens in patients with multiple myeloma progressing on lenalidomide-based maintenance therapy. <i>British Journal of Haematology</i> , 2021, 193, e23-e26.	2.5	3
29	A phase one trial of carfilzomib, bendamustine, and dexamethasone in relapsed and/or refractory multiple myeloma. <i>American Journal of Hematology</i> , 2021, 96, E243-E246.	4.1	3
30	Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to Whites: A propensity score matched analysis. <i>American Journal of Hematology</i> , 2021, 96, E455-E457.	4.1	3
31	Gene Expression Profiling Predicts Clinical Outcomes in Newly Diagnosed Multiple Myeloma Patients in a Standard of Care Setting. <i>Blood</i> , 2016, 128, 5628-5628.	1.4	3
32	Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study. <i>American Journal of Hematology</i> , 2022, 97, 719-730.	4.1	3
33	A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. <i>American Journal of Hematology</i> , 2019, 94, E319-E322.	4.1	1
34	Early Mixed T-Lymphocyte and Myeloid Chimerism Is Predictive of Disease Recurrence Following Allogeneic Stem Cell Transplantation for AML/MDS. <i>Blood</i> , 2012, 120, 3075-3075.	1.4	1
35	Low Dose Azacitidine (AZA) Reduces the Incidence of Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). <i>Blood</i> , 2012, 120, 742-742.	1.4	1
36	Acquired Therapy-Related Cytogenetic Clones in Patients Treated for Multiple Myeloma. <i>Blood</i> , 2012, 120, 4059-4059.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Low Dose Azacitidine Maintenance Therapy Following Allogeneic Stem Cell Transplantation for MDS/AML Does Not Interact with Tacrolimus Dosing or Serum Levels. <i>Blood</i> , 2012, 120, 4209-4209.	1.4	0
38	CX-5461, a Novel RNA Polymerase I Inhibitor, Is Active Against Wild-Type and Mutant p53 Myeloma Models. <i>Blood</i> , 2013, 122, 4438-4438.	1.4	0